Cognitive phenotypes in late-life depression

Sarah M. Szymkowicz,1 Claire Ryan,1 Damian M. Elson,1 Hakmook Kang,2 and Warren D. Taylor1,3
1Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN, USA
2Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA
3Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Health System, Nashville, TN, USA

ABSTRACT

Objective: To identify cognitive phenotypes in late-life depression (LLD) and describe relationships with sociodemographic and clinical characteristics.

Design: Observational cohort study

Setting: Baseline data from participants recruited via clinical referrals and community advertisements who enrolled in two separate studies.

Participants: Non-demented adults with LLD (n = 120; mean age = 66.73 ± 5.35 years) and non-depressed elders (n = 56; mean age = 67.95 ± 6.34 years).

Measurements: All completed a neuropsychological battery, and individual cognitive test scores were standardized across the entire sample without correcting for demographics. Five empirically derived cognitive domain composites were created, and cluster analytic approaches (hierarchical, k-means) were independently conducted to classify cognitive patterns in the depressed cohort only. Baseline sociodemographic and clinical characteristics were then compared across groups.

Results: A three-cluster solution best reflected the data, including “High Normal” (n = 47), “Reduced Normal” (n = 35), and “Low Executive Function” (n = 37) groups. The “High Normal” group was younger, more educated, predominantly Caucasian, and had fewer vascular risk factors and higher Mini-Mental Status Examination compared to “Low Executive Function” group. No differences were observed on other sociodemographic or clinical characteristics. Exploration of the “High Normal” group found two subgroups that only differed in attention/working memory performance and length of the current depressive episode.

Conclusions: Three cognitive phenotypes in LLD were identified that slightly differed in sociodemographic and disease-specific variables, but not in the quality of specific symptoms reported. Future work on these cognitive phenotypes will examine relationships to treatment response, vulnerability to cognitive decline, and neuroimaging markers to help disentangle the heterogeneity seen in this patient population.

Key words: cognition, cluster analysis, depression, aging, neuropsychological testing, geriatric

Introduction

Deficits in executive functioning are common in late-life depression (LLD) and associated with a range of negative clinical outcomes, including poor antidepressant response, suicidality, and conversion to dementia (Alexopoulos, 2019). Aging, regional brain atrophy, genetics, medical comorbidities including inflammation, and vascular risk processes contribute to dysfunction in fronto-subcortical brain systems such as cognitive control and reward networks, and in turn influence the cognitive presentation and clinical outcomes (Alexopoulos, 2019; He et al., 2021). These executive deficits persist despite adequate treatment and resolution of the depressive symptoms, making the individual vulnerable to depression relapse and recurrence (Alexopoulos, 2019) and hampering functional recovery (Bortolato et al., 2019).

However, there is variability in the cognitive presentation of LLD. Not all individuals with LLD exhibit executive deficits, and difficulties in other
cognitive domains (e.g. memory) may be present (Hickie et al., 2005; Thomas et al., 2009). These different cognitive presentations suggest different mechanisms, where cognitive performance may be less associated with vascular processes and more associated with Alzheimer’s disease pathology, such as lower temporal lobe/hippocampal volumes (Hickie et al., 2005; Takamiya et al., 2021), amyloid or tau burden, and APOE e4 allele (Rhodes et al., 2021). Furthermore, some individuals with LLD exhibit normal cognitive functions similar to their non-depressed same-aged peers (Morin et al., 2019; Opdebeeck et al., 2015), suggesting that, just as there is heterogeneity in clinical presentation (Alexopoulos, 2019; Gunning et al., 2021), there is heterogeneity in LLD’s cognitive presentation. Much research to date has focused on differences in cognitive performance between depressed individuals and psychiatrically healthy controls (Rock et al., 2014) and not within depressed cohorts. This may contribute to inconsistent cognitive findings across studies.

Data-driven statistical approaches, such as cluster analysis, allow for the identification of homogeneous subgroups within a larger heterogeneous data set and group individuals in a way that maximizes within subgroup and minimizes between subgroup similarities (Windgassen et al., 2018). When examining cognition in particular, these subgroups have been termed “cognitive phenotypes.” Previous research using cluster analysis and other similar methods has examined cognition within depression across the lifespan (ages 18 to 70) (Martin et al., 2020; Pu et al., 2018), identifying three cognitive phenotypes: a) cognitively “intact” or with an isolated cognitive weakness, b) cognitively “reduced” with modest deficits in a subset of cognitive functions, and c) cognitively “impaired” with deficits across most/all cognitive domains. Martin et al. (2020) reported demographic differences between the cognitive phenotypes (e.g. age, education, predicted intelligence), but no statistically significant differences in clinical factors (e.g. age of depression onset or length of current episode, presence of melancholia or anxiety) with the exception of depression severity. They also investigated whether patterns of responses on the depression rating scale differed by cognitive phenotype, and they found no statistically significant differences across items. Specific to LLD, findings have been mixed. One group reported three cognitive phenotypes (memory impairment, executive/memory impairment, and attention/memory impairment) (Lockwood et al., 2000) and another reported two phenotypes (high normal vs. lower normal) (Morin et al., 2019). In the Morin et al. (2019) study, the only factor that predicted group membership was that lower cognitive status was associated with the APOE e4 allele.

Limitations of the previous work include, in some instances, drawing conclusions from individual cognitive tests. This can be problematic, as patterns of cognitive performance within and across cognitive domains and not on a single test are more clinically meaningful (Harvey, 2012), and low scores on individual cognitive tests within a large cognitive battery in non-demented older adults are common (Mistridis et al., 2015). Together, this supports the use of cognitive domain composite scores for the current study, which combines several individual test scores into a single cognitive domain score. This limits the number of comparisons (thereby reducing type I error), reduces the influence of floor or ceiling effects from any one test, and also allows for identification of meaningful cognitive patterns at the group level.

The purpose of the current study was to investigate cognitive heterogeneity within LLD using a data-driven approach (i.e. cluster analysis) to identify cognitive phenotypes. To better understand the identified cognitive phenotypes, and to compare our findings with the broader literature, we also examined whether the identified phenotypes differed in sociodemographic and clinical characteristics. We hypothesized we would observe at least two cognitive phenotypes, one with relatively preserved cognitive functions and the other with deficits predominantly in executive functioning. We were also interested in investigating whether the cognitive phenotypes were associated with functional status and subjective cognitive complaints, given that these outcomes are related to depressive symptomology (Verhaak et al., 2014; Zlatar et al., 2018) and not examined in previous studies.

**Methods**

**Participants**

Participants were recruited from clinical referrals and community advertisements at Vanderbilt University Medical Center who enrolled in two separate studies with similar entry and exclusionary criteria. All participants were aged 60 years or older without a diagnosis of dementia or significant cognitive impairment, as assessed by review of their medical records and a score of 24 or greater on the Mini-Mental Status Examination (MMSE) (Folstein et al., 1975). Participants with LLD had a DSM-IV-TR diagnosis of Major Depressive Disorder (determined via the Mini-International Neuropsychiatric Interview; MINI) (Sheehan et al., 1998) and a score of 15 or greater on the Montgomery Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979). Exclusionary criteria included acute suicidality,
other DSM-IV-TR Axis I diagnoses (with the exception of concurrent anxiety), acute grief, current or history of psychosis, history of substance abuse or dependence over the previous three years, neurological disorders (e.g. stroke, Parkinson’s disease), chronic untreated medical conditions (e.g. diabetes, hypothyroidism), current involvement in psychotherapy, electroconvulsive therapy in the previous six months, or MRI contraindications. For both studies, participants with LLD were tapered off ineffective antidepressants prior to the initiation of any study procedures and were off medications for at least two weeks prior to clinical assessments.

Healthy never depressed elders (NDE; $n = 56$) did not meet current or historical criteria for any DSM-IV-TR Axis I disorder, nor did they have history of any mental health treatment, along with the other exclusionary criteria outlined above. The Vanderbilt University Institutional Review Board approved both of the studies. All study participants provided both written and verbal informed consent. These studies were registered with ClinicalTrials.gov (NCT01896934 and NCT02332291). We have previously reported data from both studies (Abi Zeid Daou et al., 2017, 2018; Christman et al., 2020; Gandelman et al., 2019; Taylor et al., 2020).

**Measures**

**Sociodemographic and clinical factors**

Sociodemographic (age, sex, years of education, race) and clinical factors related to depression history (family history of depression or bipolar disorder) were obtained via an interview, the MINI, and a review of available medical records. Depression severity was assessed with the MADRS. We also determined age of initial depression onset and duration of current depressive episode using a life-charting approach and supplemented with medical record data (Christman et al., 2020). Medical comorbidity was determined by the Cumulative Illness Rating Scale for Geriatrics (Miller et al., 1992), and vascular risk was quantified using the Framingham Study stroke risk prediction tool (Wolf et al., 1991).

**Functional status**

The WHO Disability Assessment Schedule 2.0 (WHODAS 2.0) (Üstün & World Health Organization, 2010) was used to measure functional status. This questionnaire is comprised of six domains where participants rate the level of difficulty they have in performing various activities on a five-point Likert scale ($1 = \text{no difficulty}$ to $5 = \text{extreme}$). The six domains include cognition, mobility, self-care, getting along (or socialization), life activities, and participation (in the community and society). The simple scoring method was used, such that scores for each item are added up without weighting of individual items, which allows for a global measure of functional status. Scores range from 36 to 180 when all items are answered, with higher scores indicating greater disability. The WHODAS 2.0 is valid and reliable measure to assess functional status in a variety of settings and populations (Federici et al., 2017). This scale was added over the course of the study, so it is only available in a subsample of participants.

**Subjective cognitive measures**

The PROMIS Applied Cognition – Abilities Scale (Saffer et al., 2015) was used to characterize cognitive complaints broadly (i.e. across multiple cognitive domains) over the previous week, which has been validated for use in older adult populations. Participants rate their responses on 8 items using a scale ranging from 1 (Not at all) to 5 (Very much), with total scores ranging from 8 to 40. Higher scores indicate better perceived cognitive functioning. This measure was only available in a subsample of participants due to addition later in the course of the study.

**Objective cognitive measures**

All participants completed paper-and-pencil cognitive tests focused on cognitive domains affected by aging and LLD and used in our previous work (Christman et al., 2020; Gandelman et al., 2019). These included the Wechsler Adult Intelligence Scale-III (WAIS-III) Digit Span (forward and backward), Symbol-Digit Modality Test (SDMT), Golden Stroop, Trail Making Test (Parts A and B), Shipley Vocabulary subtest, Wechsler Memory Scale-Revised (WMS-R) Logical Memory (LM), Benton Visual Retention Test (BVRT), Initiation/Perseveration (I/P) subtests of the Dementia Rating Scale (DRS), and letter fluency (FAS trials), along with several measures from the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD; 15-item Boston Naming Test (BNT), wordlist memory, and constructional praxis).

**Statistical analysis**

Statistical analyses were conducted using SPSS 27.0 software (IBM Corp., Armonk, NY, USA). Prior to the cluster analyses, the individual cognitive test scores were normed against the entire sample of LLD and NDE and standardized $z$-scores were obtained without correcting for demographics. Time to completion for both Trails A and B was reversed scored prior to standardization so that all measures were in the same direction (i.e. higher scores equate to better performance). Five empirically derived cognitive domain composites (Lezak et al., 2012) were developed from the individual tests by averaging the $z$-scores of the tests within each
domain. These consisted of attention/working memory (WAIS-III Digit Span forward and backward), processing speed (SDMT total correct, Trails A time to completion, and Stroop Color Naming total correct), language (BNT-15 total correct, Vocabulary total correct, and Stroop Word Reading total correct), episodic recall (CERAD wordlist delayed recall total correct, CERAD constructional praxis delayed recall total correct, WMS-R LM-II total correct, and BVRT immediate recall total correct), and executive functions (DRS 1/P total correct, FAS total correct, Stroop Color–Word total correct, and Trails B time to completion). Internal consistency (Cronbach’s α) of the calculated domain composites were attention/working memory = 0.702, processing speed = 0.740, language = 0.256, episodic recall = 0.759, and executive functions = 0.637. The obtained standardized cognitive domain variables were subsequently used in the analyses.

Differences between LLD and NDE in sociodemographic, clinical, and cognitive variables were examined using independent sample t-tests for continuous variables and chi-square tests for categorical variables (see Supplemental Table 1). As the purpose of this study was to investigate cognitive phenotypes within LLD (and not necessarily between LLD and NDE), the NDE group in this study were only used for comparative purposes to describe the overall sample.

A series of cluster analyses were conducted to classify and cross-validate observed patterns based on the standardized cognitive domain variables. Hierarchical agglomerative clustering via Ward’s method with squared Euclidean distance was first used (Murtagh and Legendre, 2014; Ward, 1963). The optimal number of clusters was determined by identifying clusters with large increases in the agglomeration distance coefficient, along with visual inspection of the dendrogram. Cluster solutions were cross-validated using K-means clustering, whereby individuals are iteratively assigned to the cluster they are most similar to based on cluster means and simple Euclidean distance metrics (Steinley, 2006). Four separate cluster solutions were explored, ranging from two to five clusters, via examination of the final cluster centroids and number of cases in each cluster. Consensus between the results of the hierarchical and k-means cluster analyses was determined with cross-tabulations and chi-square independence tests with cluster membership. All cases were retained in the initial analyses; however, one participant was determined to be an outlier (i.e. participant was identified as a separate, unique cluster across solutions and techniques) and was removed before re-assessing final cluster solutions.

After determining the optimal cluster solution, the derived clusters from the hierarchical analysis (i.e. “cognitive phenotypes”) were compared on sociodemographic and clinical factors, functional status, subjective cognitive measures, and cognitive composites to understand group differences between groups via Kruskal–Wallis (due to the non-normality of several variables) and chi-square tests. We then conducted a mixed analysis of covariance (ANCOVA) with the individual cognitive composites as the repeated factor and cognitive phenotype as the between-subject factor, with any significant sociodemographic or clinical factors identified in the previous analysis as covariates (after checking for the normality of the residuals). Effect sizes were calculated using partial eta squared ($\eta^2$), with 0.01 suggesting small effects, 0.06 medium effects, and > 0.14 large effects (Cohen, 1969). To determine LLD cognitive phenotype membership given any significant sociodemographic or clinical factors in the initial analysis, a multinomial logistic regression was conducted, with the “High Normal” group considered as the reference category.

Lastly, exploratory analyses examined whether the pattern of responses on individual MADRS items differed between cognitive phenotypes using a multivariate ANCOVA (MANCOVA) and also further explored the “High Normal” cognitive phenotype using similar methods as above (i.e. Mann–Whitney U-tests for differences in sociodemographic and clinical characteristics, mixed ANCOVA for differences in cognitive performance; see Supplemental Methods).

**Results**

**Overall sample**

The LLD had significantly lower education, were predominantly Caucasian, had greater family history of depression, more medical comorbidities, and had higher scores on the MADRS, as well as greater perceived disability and overall subjective cognitive complaints when compared to the NDE group (Supplemental Table 1). The LLD group also performed significantly lower on the processing speed and executive function domains compared to NDE (Supplemental Table 1), but the scores overall were still within the normal range.

**Cluster solutions**

Results of Ward’s method for hierarchical clustering suggested a three- or four-cluster solution based on examination of the dendrogram and agglomeration coefficient changes, along with number of cases per cluster. To cross-validate, k-means cluster analysis
similarly indicated that three or four clusters should be retained. Comparison of the two clustering techniques revealed a highly similar three-cluster solution, with greater agreement in the proportion of cases assigned to the same cluster in the three- (81–97%) versus four- (74–100%) cluster solution. A chi-square test of independence indicated that there was a significant relationship between likelihood of being assigned to the same cluster using each clustering method in the three-cluster solution, \(X^2(4, N = 119) = 160.78, p < 0.001\). Based on these findings, we selected three clusters as our optimal cluster solution, given they provided the most appropriate balance between sample size and clinical usefulness in terms of the cognitive patterns, and used the hierarchical clusters for all subsequent analyses. Using graphical exploration of the cognitive domain composites by cluster, different cognitive profiles were observed, reflecting “High Normal” \((n = 47)\), “Reduced Normal” \((n = 35)\), and “Low Executive Function” \((n = 37)\) groups

**Group differences in sociodemographic, clinical factors, and cognitive functions**

The “High Normal” group was significantly younger, more educated, predominantly Caucasian, and had fewer vascular risk factors and a higher MMSE compared to the “Low Executive Function” group \((p’s < 0.003; \text{Table 1})\). The “High Normal” group also were significantly more educated than “Reduced Normal” group. No group differences were observed on other sociodemographic or clinical factors, including depression-related variables, functional status, or subjective cognition. In terms of cognitive functions, the “High Normal” group performed significantly better across all cognitive composites compared to both the “Reduced Normal” and “Low Executive Function” groups \((p’s < 0.05)\). The “Reduced Normal” group performed better than the “Low Executive Function” group measures of attention/working memory, processing speed, and executive functions \((p’s < 0.001)\).

In the subsequent mixed ANCOVA analyses controlling for covariates that were significantly different between groups (i.e. age, education, race, Framingham score, and MMSE) and overall level of depression via the MADRS, group membership significantly predicted performance across the cognitive domains \((p’s < 0.001, \eta^2_p > 0.18)\), with a similar pattern of findings as reported above with the exception of processing speed that no longer differed between the “High Normal” and “Reduced Normal” groups (Table 2 and Figure 1a).

**Prediction of group membership**

While the model included age, education, race, Framingham score, MMSE, and MADRS, only age, education, and MMSE significantly influenced group membership (Model \(X^2(12) = 69.51, p < 0.001\)). Using the “High Normal” cluster as the reference group, participants older in age and with less education were more likely to be in the “Reduced Normal” group and those older in age, with less education, and lower MMSE scores were more likely to be in the “Low Executive Function” group (Table 3).

**Exploration of cognitive phenotypes and depressive symptom patterns**

When examining response patterns on the MADRS, the main effect of cognitive phenotype was not statistically significant \((F(20, 216) = 0.77, p = 0.752, \eta^2_p = 0.07)\). This remained unchanged when repeated with age, education, race, Framingham score, MMSE, and total MADRS as covariates \((F(18, 204) = 1.18, p = 0.279, \eta^2_p = 0.09; \text{Supplemental Figure 1a})\).

**Exploration of the “High Normal” phenotype**

We further explored the “High Normal” cognitive phenotype, as the four-cluster solution suggested this group may differ in attention/working memory abilities (but the sample sizes overall were too small to be used in primary analyses). The two subgroups (“High Attention/Normal” \([n = 26]\) and “Low Attention/Normal” \([n = 21]\)) significantly differed in performance on attention / working memory \((p < 0.001)\), but not across the other cognitive composites. The length of the current depressive episode was significantly less for the “Low Attention/Normal” group compared to the “High Attention/Normal” group \((p = 0.032)\), but the groups did not significantly differ on any other sociodemographic or clinical factors, functional status, or subjective cognition (Supplemental Table 2). In subsequent analyses controlling for length of current depressive episode and total MADRS, cognitive phenotype significantly predicted performance in the attention/working memory domain \((F(1, 42) = 109.25, p < 0.001, \eta^2_p = 0.72)\), but not for other cognitive domains \((p’s > 0.222; \text{Figure 1b})\). These two cognitive phenotypes did not significantly differ in their response pattern on the MADRS \((F(9, 36) = 1.57, p = 0.154, \eta^2_p = 0.30)\). This remained unchanged when repeated with length of depressive episode and total MADRS as covariates \((F(9, 34) = 1.87, p = 0.091, \eta^2_p = 0.33; \text{Supplemental Figure 1b})\).
Table 1. Differences in sociodemographic, clinical factors, and cognitive domain functions across clusters

|                      | Cluster 1 (N = 47) | Cluster 2 (N = 37) | Cluster 3 (N = 35) | Omnibus Kruskal-Wallis H-test (or Chi-square) & p-value | Post hoc cluster comparison *p < 0.05 **p < 0.01 ***p < 0.001 |
|----------------------|--------------------|--------------------|--------------------|----------------------------------------------------------|-------------------------------------------------------------|
| **Sociodemographics**|                    |                    |                    |                                                          |                                                             |
| Age                  | 64.60 (4.21)       | 67.11 (5.23)       | 68.97 (5.78)       | 13.21                                                   | 1-2                                                        |
|                      |                    |                    |                    |                                                          | 1-3***                                                     |
| Sex, female n (%)    | 27 (57.4)          | 23 (62.2)          | 21 (60.0)          | 0.19                                                    | 2-3                                                        |
|                      |                    |                    |                    |                                                          |                                                             |
| Education, years     | 16.09 (2.28)       | 13.95 (1.84)       | 14.60 (2.00)       | 18.75                                                   | 1-2                                                        |
|                      |                    |                    |                    |                                                          | 1-3*                                                       |
|                      |                    |                    |                    |                                                          |                                                             |
| Race, Caucasian n (%)| 45 (95.7)          | 34 (91.9)          | 27 (77.1)          | <0.001                                                  | 2-3                                                        |
|                      |                    |                    |                    |                                                          |                                                             |
| **Clinical Factors** |                    |                    |                    |                                                          |                                                             |
| MADRS                | 26.02 (5.51)       | 25.68 (6.58)       | 26.54 (4.99)       | 0.21                                                    |                                                             |
|                      |                    |                    |                    |                                                          |                                                             |
| Age at depression onset, years | 35.83 (18.02) | 35.08 (22.23) | 35.50 (20.59) | 0.30 | – |
|                      |                    |                    |                    |                                                          |                                                             |
| Length of current episode, days | 1118.72 (1182.08) | 820.94 (755.41) | 1030.24 (849.46) | 0.91 | – |
|                      |                    |                    |                    |                                                          |                                                             |
| Family history of depression n (%) | 32 (68.1) | 24 (66.7) | 22 (62.9) | 0.25 | – |
|                      |                    |                    |                    |                                                          |                                                             |
| Family history of bipolar disorder n (%) | 9 (19.6) | 2 (5.7) | 8 (22.9) | 0.882 | – |
|                      |                    |                    |                    |                                                          |                                                             |
| Cumulative Illness Rating Scale – Geriatrics | 5.13 (3.73) | 5.41 (3.23) | 6.00 (2.77) | 2.90 | – |
|                      |                    |                    |                    |                                                          |                                                             |
| Framingham vascular risk | 8.53 (3.71) | 9.81 (3.52) | 11.74 (3.20) | 14.39 | 1-2 |
|                      |                    |                    |                    |                                                          | 1-3***                                                     |
| WHODAS 2.0           | 75.69 (18.73)      | 76.87 (22.24)      | 76.19 (17.85)      | 0.32                                                    |                                                             |
|                      |                    |                    |                    |                                                          |                                                             |
| PROMIS               | 24.97 (7.86)       | 21.63 (7.34)       | 23.33 (6.46)       | 0.851                                                   |                                                             |
|                      |                    |                    |                    |                                                          |                                                             |
| MMSE                 | 29.67 (0.56)       | 29.24 (0.93)       | 28.74 (1.38)       | 12.31                                                   | 1-2                                                        |
|                      |                    |                    |                    |                                                          | 1-3**                                                      |
|                      |                    |                    |                    |                                                          |                                                             |
| **Cognitive Domain Functions** |                |                    |                    |                                                          |                                                             |
| Attention / working memory (z-score) | 0.62 (0.82) | −0.13 (0.42) | −0.86 (0.52) | 58.24 | 1-2** |
|                      |                    |                    |                    |                                                          | 1-3***                                                     |
| Processing speed (z-score) | 0.43 (0.43) | 0.07 (0.41) | −0.88 (0.65) | 65.81 | 1-2* |
|                      |                    |                    |                    |                                                          | 1-3***                                                     |
|                      |                    |                    |                    |                                                          |                                                             |

S. M. Szymkowicz et al. https://doi.org/10.1017/S1041610222000515 Published online by Cambridge University Press
Table 1. Continued

| Cluster 1 | Cluster 2 | Cluster 3 | Omnibus Kruskal-Wallis Test (or Chi-Square) & P-Value | Post Hoc Cluster Comparison |
|-----------|-----------|-----------|-----------------------------------------------------|-----------------------------|
| High Normal (N = 47) | Reduced Normal (N = 37) | Low Executive Functions (N = 35) | | |
| Language (z-score) | 0.41 (0.45) | −0.19 (0.70) | −0.46 (0.46) | 43.16 | <0.001 |
| Episodic recall (z-score) | 0.55 (0.47) | −0.38 (0.61) | −0.39 (0.71) | 49.00 | 1–2*** |
| Executive functions (z-score) | 0.42 (0.41) | −0.06 (0.31) | −0.75 (0.66) | 61.32 | 1–2*** |

Notes: MADRS: Montgomery Asberg Depression Rating Scale; WHODAS: WHO Disability Assessment Schedule; PROMIS: PROMIS Applied Cognition – Abilities Scale; MMSE: Mini-Mental Status Examination. Due to missing data, the following variables have different sample sizes: Age at depression onset (N = 46, 36, 34), Length of current episode (N = 46, 33, 34), Family history of depression (N = 47, 36, 35), Family history of bipolar disorder (N = 46, 35, 35), WHODAS 2.0 (N = 39, 30, 21), PROMIS (N = 31, 24, 15), and MMSE (N = 46, 37, 35).

Figure 1. Subgroups in late-life depression based on cluster analysis of neurocognitive performance. (a) Three cognitive phenotypes identified in the full depression sample. (b) Exploratory analysis of “High Normal” phenotype showing significant differences in attention/working memory performance. Both sets of results are presented after covariate adjustment.
Table 2. ANCOVA results of cluster group predicting cognitive domain performance

| COGNITIVE DOMAIN            | CLUSTER 1 HIGH NORMAL | CLUSTER 2 REDUCED NORMAL | CLUSTER 3 LOW EXECUTIVE FUNCTIONS | F-TEST P-VALUE | PARTIAL ETA SQUARED | CLUSTER COMPARISON | POST HOC P-VALUE (BONFERRONI) | 95% CONFIDENCE INTERVAL FOR DIFFERENCE |
|-----------------------------|------------------------|--------------------------|-----------------------------------|----------------|----------------------|---------------------|-----------------------------|----------------------------------------|
| Attention / working memory  | 0.62 (0.11)            | −0.19 (0.11)             | −0.84 (0.12)                      | 35.09 <0.001   | 0.392                | 1-2                  | <0.001                      | 0.41, 1.21                             |
| Processing speed            | 0.33 (0.08)            | 0.08 (0.08)              | −0.76 (0.09)                      | 38.07 <0.001   | 0.411                | 1-2                  | 1-3 <0.001                  | 1.04, 1.89                             |
| Language                    | 0.34 (0.09)            | −0.13 (0.09)             | −0.41 (0.10)                      | 13.58 <0.001   | 0.199                | 1-2                  | 2-3 <0.001                  | 0.55, 1.13                             |
| Episodic recall             | 0.35 (0.09)            | −0.31 (0.09)             | −0.20 (0.10)                      | 11.69 <0.001   | 0.177                | 1-2                  | 2-3 <0.001                  | −0.03, 0.59                            |
| Executive functions         | 0.36 (0.08)            | −0.07 (0.08)             | −0.66 (0.09)                      | 31.54 <0.001   | 0.367                | 1-2                  | 1-3 <0.001                  | 0.14, 0.72                             |

Note: z-score cognitive composites, with mean of 0 and SD of 1. Estimated mean and standard error reported, controlling for age, years of education, race, Framingham score, Mini-Mental Status Examination, and total Montgomery Asberg Depression Rating Scale. Df for all models = 2, 109. Bold represents post hoc significance at p < 0.05.
Table 3. Predicting cognitive phenotype membership: Multinomial logistic regression

| PREDICTORS | B (SE) | OR (95% CI) | P-VALUE |
|------------|--------|-------------|---------|
| Cluster 2 (Reduced Normal) vs. Cluster 1 | | | |
| Age | 0.24 (0.08) | 1.27 (1.08, 1.48) | 0.003 |
| Education | −0.67 (0.16) | 0.51 (0.38, 0.70) | <0.001 |
| Cluster 3 (Low Executive Functions) vs. Cluster 1 | | | |
| Age | 0.27 (0.08) | 1.31 (1.11, 1.53) | 0.001 |
| Education | −0.54 (0.16) | 0.58 (0.42, 0.80) | <0.001 |
| MMSE | −0.90 (0.37) | 0.41 (0.20, 0.84) | 0.014 |

Note. Model $X^2 (12) = 69.51, p < 0.001$. Model included age, education, race, Framingham score, MMSE, and MADRS. Cluster 1 (High Normal) was used as the reference group. OR: odds ratio; CI: confidence interval; MMSE: Mini-Mental Status Examination; MADRS: Montgomery Asberg Depression Rating Scale.

Discussion

This study investigated cognitive phenotypes in a clinical cohort of elders with LLD. Using cluster analyses, we identified three cognitive phenotypes in LLD (with large to very large effects). These slightly differed in sociodemographic and clinical factors, but not in the quality of specific symptoms reported, functional status, or subjective cognitive complaints. After covariate adjustment, the “High Normal” phenotype had cognitive performance $> 0.30$ standard deviations (SDs) above the mean across the five cognitive domains assessed (i.e. attention/working memory, processing speed, language, episodic recall, and executive functions), with a relative strength in attention/working memory. The “Reduced Normal” phenotype generally had cognitive performances at or just below the mean, with a relative weakness in episodic recall. The “Low Executive Function” phenotype demonstrated lowest scores across attention/working memory, processing speed, and executive function domains (>0.65 SDs below the mean). These data demonstrate partial support for our hypothesis, as we found a group defined by preserved cognitive functions and another with weakness predominantly in executive functions. We also identified a third intermediary group with lower cognitive scores overall, but that were still considered within the “normal” range.

Past meta-analyses suggest that adults with depression perform 0.5 to 1.0 SDs below healthy comparison subjects on cognitive tasks (Rock et al., 2014), particularly on measures of attention and executive functions, with depression-related executive dysfunction greatest in older ages (Dotson et al., 2020). By using $z$-score cognitive domain composites, instead of single tests or dichotomous “intact vs. impaired” classification, our study demonstrated that cognitive functions in LLD lie on a continuum, with some individuals exhibiting preserved cognitive functions and others having lower performance in selective cognitive domains. Using similar clustering methods in an age diverse depression sample (ranging from 18 to 70 years), Martin et al. (2020) found a “cognitively impaired” subgroup that performed $> 1.0$ SD below the mean on all cognitive outcome measures, with verbal learning and memory largely affected. In contrast, both the “Reduced Normal” and “Low Executive Function” phenotypes in the current study did not meet this liberal cutoff for clinically significant cognitive impairment (Jak et al., 2009). While our study demonstrates a range of cognitive presentations in LLD, we did not find a globally impaired group, which may be an artifact of sample or methodological differences across studies (i.e. use of cognitive composites versus individual cognitive tests).

The observed “Low Executive Function” phenotype is consistent with the ‘depression-executive dysfunction syndrome’ characterized by Alexopoulos and colleagues (Alexopoulos, 2019; Lockwood et al., 2000; Morimoto et al., 2020). This phenotype has significantly higher vascular burden compared to the “High Normal” phenotype based on their Framingham score, and it is hypothesized that this subgroup may also have greater white matter changes evident on neuroimaging that may contribute to this cognitive presentation (Alexopoulos, 2019; Oberlin et al., 2022; Taylor et al., 2013). Interestingly, we found two phenotypes with relative preservation of cognitive functions. While cognitive functions were entirely within normal limits, the “Low Normal” group had a relative weakness in episodic recall, which is similar to what was seen in the “lower cognitive class” of the Morin et al. (2019) study. Their study found APOE e4 allele status predicted membership in this group and suggested they may be at greater risk for cognitive decline despite currently normal cognitive performance. We do not have similar genetic data available, but this is an interesting avenue for future exploration and consideration for this phenotype’s potential vulnerability to
develop Alzheimer’s disease (Diniz et al., 2013). We also observed the presence of a group of individuals with entirely preserved cognitive functions, where protective and resiliency factors related to cognition may be studied (Laird et al., 2019a, 2019b). This preserved group has also been shown in age diverse (Martin et al., 2020) and geriatric depression samples (Morin et al., 2019), as well as in bipolar disorder (Lima et al., 2019; Montejo et al., 2022).

Although the cognitive phenotypes differed in cognitive performance, they did not differ on many sociodemographic or clinical measures. Factors unique to depression, such as age at depression onset (Mackin et al., 2014), did not differentiate cognitive phenotype. Concordant with past studies (Lockwood et al., 2000; Morin et al., 2019), we also did not observe that overall depression severity distinguished between phenotypes. This supports that cognitive dysfunction may occur independent from current depression severity in older adults and is in accord with literature showing that depression severity is not strongly associated with cognitive functioning (Keilp et al., 2018; McClintock et al., 2010; Szymkowicz et al., 2020). Similar to the Martin et al. (2020) study, we additionally did not find that clinician ratings of depression symptom severity on individual MADRS items differentiated between the cognitive phenotypes. Unfortunately, data on other measures relevant for recurrent depression were not assessed, such as measures of chronicity, accumulated severity, or inpatient history, which may have interesting implications and should be investigated in future studies.

Previous evidence suggests relationships between level of cognitive dysfunction and disability in depression (LaMonica et al., 2019; Riddle et al., 2015). However, our study and others (Pu et al., 2018) did not find support for self-report of functional status significantly differentiating between cognitive phenotypes. Regardless of phenotype, participants in the current study reported mild disability that was on average significantly higher than the NDE group who reported minimal average disability. This may be due to our sample not having a subgroup that crossed a threshold for true cognitive impairment and would be expected to have higher ratings of disability.

Finally, there is a mixed evidence on the importance of subjective cognitive complaints in older adults. Some studies suggest relevance of cognitive complaints to preclinical Alzheimer’s disease (Lin et al., 2019; Rabin et al., 2017), and others suggest the symptoms are more related to depressive symptoms and not cognitive decline (Sabatini et al., 2021; Zlatar et al., 2018). In the current study, compared to NDE, participants with LLD reported greater subjective cognitive complaints; however, the severity of complaints did not differentiate the cognitive phenotypes. Regardless of how well (or poorly) participants performed on objective cognitive measures, they rated their perceived cognitive difficulties comparably, which may reflect depression-related factors such as pessimism, rumination, and low self-efficacy (Schlosser et al., 2020; Smit et al., 2021). This suggests that relying on reports of subjective cognitive complaints is not the ideal methodology for identifying subtle neurocognitive dysfunctions in otherwise functional individuals.

The current study had several strengths, including the use of a well-defined cohort of depressed elders who were off antidepressant medications at the time of testing and who underwent detailed clinical evaluations. Additionally, all participants underwent a clinically relevant neuropsychological battery that we were able to use to derive empirically supported cognitive domain composites and we had access to psychiatrically healthy NDE in order to locally norm the cognitive data. Despite these strengths, there are limitations. First, our sample was predominantly Caucasian, so it is unclear how these cognitive phenotypes may present in more diverse geriatric depression samples, where factors such as degree of acculturation or impact of systemic racism may play a larger role in cognitive, behavioral, and health outcomes (Martinez-Miller et al., 2020; Miller et al., 2011; Ray et al., 2022). Our sample was well-educated overall (> high school, on average), and we cannot generalize these findings to those LLD with lower educational levels. Measures of performance validity or estimated premorbid cognitive functioning were not available, and thus, we are limited in our ability to discuss effects or implications of these. Some items (e.g. mood questionnaires, subjective cognition) were not administered to the entire sample, which may have affected findings. It may be worth investigating relationships between cognitive phenotypes and specific mood symptoms or profiles in the future using a larger data set. The cross-sectional design precludes our ability to infer causality or determine whether these cognitive phenotypes change with time or treatment. The current study is based on a clinical sample of LLD, which may not represent community-based older adults with non-clinical or subthreshold depressive symptoms. Importantly, these cognitive phenotypes have not been validated in an independent sample, which is an important area for future investigation.

In conclusion, results of the current study identified three LLD subgroups based on neurocognitive performance. Identification of cognitive phenotypes in LLD may help with tailoring treatments or
interventions based upon specific presentation (e.g. use of neurobiologically informed cognitive remediation for dysexecutive cognitive profiles (Morimoto et al., 2020), psychoeducation, and cognitive-behavioral therapy for preserved cognitive profiles (Dafsari et al., 2019)). Use of cognitive phenotypes may also allow for better selection of participants for pharmacological and non-pharmacological clinical trials, as well as allow for a more targeted assessment of clinical predictors and underlying mechanisms of each cognitive phenotype.

Conflict of interest

None.

Author contributions

SMS was involved with conception and design of this substudy, data analysis and interpretation, and manuscript preparation. CR was involved with manuscript preparation. DME and HK also assisted with data analysis and interpretation. WDT was involved with conception and design of the parent studies, as well as this substudy, data interpretation, and manuscript preparation. All authors approved the final version of this manuscript.

Acknowledgements

This work was supported by NIH grants R01MH102246, R01MH121620, and R21MH099218. It also utilized resources supported by the National Center for Advancing Translational Science, grants UL1TR000445 and UL1TR002243. Dr Taylor would additionally like to acknowledge salary support from the Tennessee Valley Healthcare System Geriatric Research Education and Clinical Center (GRECC).

Supplementary material

To view supplementary material for this article, please visit https://doi.org/10.1017/S1041610222000515

References

Abi Zeid Daou M., Boyd B. D., Donahue M. J., Albert K. and Taylor W. D. (2017). Frontocingulate cerebral blood flow and cerebrovascular reactivity associated with antidepressant response in late-life depression. *Journal of Affective Disorders*, 215, 103–110. DOI 10.1016/j.jad.2017.03.027.

Abi Zeid Daou M., Boyd B. D., Donahue M. J., Albert K. and Taylor W. D. (2018). Anterior–posterior gradient differences in lobar and cingulate cortex cerebral blood flow in late-life depression. *Journal of Psychiatric Research*, 97, 1–7. DOI 10.1016/j.jpsychires.2017.11.005.

Alexopoulos, G. S. (2019). Mechanisms and treatment of late-life depression. *Translational Psychiatry*, 9, 188. DOI 10.1038/s41398-019-0514-6.

Bortolato, B., et al. (2019). Cognitive remission: a novel objective for the treatment of major depression? *BMC Medicine*, 14, 9. DOI 10.1186/s12916-016-0560-3.

Christman, S., et al. (2020). Accelerated brain aging predicts impaired cognitive performance and greater disability in geriatric but not midlife adult depression. *Translational Psychiatry*, 10, 317. DOI 10.1038/s41398-020-01004-z.

Cohen, J. (1969). *Statistical Power Analysis for the Behavioural Sciences*. New York, NY: Academic Press.

Dafsari, F. S., et al. (2019). Cognitive behavioural therapy for the treatment of late life depression: study protocol of a multicentre, randomized, observer-blinded, controlled trial (CBTlate). *BMC Psychiatry*, 19, 423. DOI 10.1186/s12888-019-2412-0.

Diniz B. S., Butters M. A., Albert S. M., Dew M. A., Reynolds C. F. 3rd (2013). Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. *British Journal of Psychiatry*, 202, 329–335. DOI 10.1192/bjp.bp.112.118307.

Dotson, V. M., et al. (2020). Depression and cognitive control across the lifespan: a systematic review and meta-analysis. *Neuropsychology Review*, 30, 461–476. DOI 10.1007/s11065-020-09436-6.

Federici S., Bracalenti M., Meloni F., Luciano J. V. (2017). World Health Organization disability assessment schedule 2.0: an international systematic review. *Disability and Rehabilitation*, 23, 2347–2380. DOI 10.1080/09638288.2016.1223177.

Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. *Journal of Psychiatric Research*, 12, 189–198. DOI 10.1016/0022-1899(75)90026-6.

Gandelman, J. A., et al. (2019). Intrinsic functional network connectivity is associated with clinical symptoms and cognition in late-life depression. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, 4, 160–170. DOI 10.1016/j.bpsc.2018.09.003.

Gunning F. M., Oberlin L. E., Schier M. and Victoria L. W. (2021). Brain-based mechanisms of late-life depression: implications for novel interventions. *Seminars in Cell & Developmental Biology*, 116, 169–179. DOI 10.1016/j.semcdb.2021.05.002.

Harvey, P. D. (2012). Clinical applications of neuropsychological assessment. *Dialogues in Clinical Neuroscience*, 14, 91–99. DOI 10.31877/DCNS.20212.14.1/pharvey.

He, X., et al. (2021). Association of white matter integrity with executive function and antidepressant treatment outcome in patients with late-life depression. *American Journal of Geriatric Psychiatry*, 29, 1188–1198. DOI 10.1016/j.jagp.2021.01.004.
Hickie, I., et al. (2005). Reduced hippocampal volumes and memory loss in patients with early- and late-onset depression. *British Journal of Psychiatry*, 186, 197–202. DOI 10.1192/bjp.186.3.197.

Jak, A. J., et al. (2009). Quantification of five neuropsychological approaches to defining mild cognitive impairment. *American Journal of Psychiatry*, 17, 368–375. DOI 10.1097/JGP.0b013e31819431d5.

Kelp J. G., Madden S. P., Gorlyn M., Burke A. K., Oquendo M. A. and Mann J. J. (2018). The lack of meaningful association between depression severity measures and neurocognitive performance. *Journal of Affective Disorders*, 241, 164–172. DOI 10.1016/j.jad.2018.08.034.

Laird, K. T., et al. (2019a). Clinical correlates of resilience factors in geriatric depression. *International Psychogeriatrics*, 31, 193–202. DOI 10.1017/S1041610217002873.

Laird K. T., Lavretsky H., Wu P., Krause B. and Siddarth P. (2019b). Neurocognitive correlates of resilience in late-life depression. *American Journal of Geriatric Psychiatry*, 27, 12–17. DOI 10.1016/j.jagp.2018.08.009.

LaMonica, H. M., et al. (2019). Disability in older adults across the continuum of cognitive decline: Unique contributions of depression, sleep disturbance, cognitive deficits and medical burden. *International Psychogeriatrics*, 31, 1611–1625. DOI 10.1017/S1041610218002144.

Lezak, M. D., et al. (2012). *Neuropsychological Assessment*. 5th edition, New York, NY: Oxford University Press, Inc.

Lim, P., et al. (2019). Identifying cognitive subgroups in bipolar disorder: a cluster analysis. *Journal of Affective Disorders*, 246, 252–261. DOI 10.1016/j.jad.2018.12.044.

Lin Y., Shan P.-Y., Jiang W.-J., Sheng C. and Ma L. (2019). Subjective cognitive decline: preclinical manifestation of Alzheimer’s disease. *Neurological Sciences*, 40, 41–49. DOI 10.1007/s10072-018-3620-y.

Lockwood K. A., Alexopoulos G. S., Kakuma T. and Van Gorp W. G. (2000). Subtypes of cognitive impairment in depressed older adults. *American Journal of Geriatric Psychiatry*, 8, 201–208. DOI 10.1097/00019442-20000800-00004.

Mackin, R. S., et al. (2014). Association of age at depression onset with cognitive functioning in individuals with late-life depression and executive dysfunction. *American Journal of Geriatric Psychiatry*, 22, 1633–1641. DOI 10.1016/j.jagp.2014.02.006.

Martin, D. M., et al. (2020). Neurocognitive subgroups in major depressive disorder. *Neuropsychology*, 36, 726–734. DOI 10.1037/neu0000626.

Martinez-Miller, E. E., et al. (2020). Longitudinal associations of US acculturation with cognitive performance, cognitive impairment, and dementia: the sacramento area latino study on aging. *American Journal of Epidemiology*, 189, 1292–1305. DOI 10.1093/aje/kwaa088.

McClinkton S. M., Husain M. M., Greer T. L. and Cullum C. M. (2010). Association between depression severity and neurocognitive function in major depressive disorder: a review and synthesis. *Neuropsychology*, 24, 9–34. DOI 10.1037/a0017336.

Miller M. J., Yang M., Farrell J. A. and Lin L-Ling (2011). Racial and cultural factors affecting the mental health of Asian Americans. *American Journal of Orthopsychiatry*, 8, 489–497. DOI 10.1111/j.1939-0025.2011.01118.x.

Miller, M., et al. (1992). Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale. *Psychiatry Research*, 41, 237–246. DOI 10.1016/0165-1781(92)90005-n.

Mistridis, P., et al. (2015). Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer’s Disease-Neuropsychological Assessment Battery (CERAD). *European Journal of Psychiatry and Clinical Neuroscience*, 265, 407–417. DOI 10.1007/s00406-0571-z.

Montejo, L., et al. (2022). Identifying neurocognitive heterogeneity in older adults with bipolar disorder: a cluster analysis. *Journal of Affective Disorders*, 298, 522–531. DOI 10.1016/j.jad.2021.11.028.

Montgomery, S. and Asberg, M. (1979). A new depression scale designed to be sensitive to change. *British Journal of Psychiatry*, 134, 382–389. DOI 10.1192/bjp.134.4.382.

Morimoto, S. S., et al. (2020). Targeting cognitive control deficits with neuroplasticity-based computerized cognitive remediation in patients with geriatric major depression: a randomized, double-blind, controlled trial. *American Journal of Geriatric Psychiatry*, 28, 971–980. DOI 10.1016/j.jagp.2020.05.023.

Morin, R. T., et al. (2019). Latent classes of cognitive functioning among depressed older adults without dementia. *Journal of the International Neuropsychological Society*, 25, 1–10. DOI 10.1017/S1355617719000596.

Murtagh, F. and Legendre, P. (2014). Ward’s hierarchical agglomerative clustering method: which algorithms implement Ward’s criterion? *Journal of Classification*, 31, 274–295. DOI 10.1007/s00357-014-9161-z.

Oberlin, L. E., et al. (2022). Late-life depression accentuates cognitive weaknesses in older adults with small vessel disease. *Neuropsychopharmacology*, 47, 580–587. DOI 10.1038/s41386-021-00973-z.

Opdebeeck C., Quinn C., Nelis S. M. and Clare L. (2015). Does cognitive reserve moderate the association between mood and cognition? A systematic review. *Reviews in Clinical Gerontology*, 25, 181–193. DOI 10.1017/S0167852714000159.

Pu S., Noda T., Setoyama S. and Nakagome K. (2018). Empirical evidence for discrete neurocognitive subgroups in patients with non-psychotic major depressive disorder: clinical implications. *Psychological Medicine*, 48, 2717–2729. DOI 10.1017/S003329171800034X.

Rabin, L. A., Smart, C. M. and Amariiglo, R. E. (2017). Subjective cognitive decline in preclinical Alzheimer’s disease. *Annual Review of Clinical Psycholog*, 13, 369–396. DOI 10.1146/annurev-clinpsy-032816-045136.

Ray, C. G. L., et al. (2022). Current status of inclusion of black subjects in neuropsychological studies: a scoping review and call to action. *The Clinical Neuropsychologist*, 36, 227–244. DOI 10.1080/13854046.2021.2019314.

Rhodes, E., et al. (2021). The impact of amyloid burden and APOE on rates of cognitive impairment in late life depression. *Journal of Alzheimer’s Disease*, 80, 991–1002. DOI 10.3233/JAD-201089.

Riddle M., McQuoid D. R., Potter G. G., Steffens D. C. and Taylor W. D. (2015). Disability but not social support...
predicts cognitive deterioration in late-life depression. *International Psychogeriatrics*, 27, 707–714. DOI 10.1017/S10416102140022543.

Rock P. L., Roiser J. P., Riedel W. J. and Blackwell A. D. (2014). Cognitive impairment in depression: a systematic review and meta-analysis. *Psychological Medicine*, 44, 2029–2040. DOI 10.1017/S0033291713002535.

Sabatini, S., Woods, R. T., Ukoumunne, O. C., Ballard, C., Collins, R. and Clare, L. (2021). Associations of subjective cognitive and memory decline with depression, anxiety, and two-year change in objectively-assessed global cognition and memory. *Aging, Neuropsychology, and Cognition*, 1–27. DOI 10.1080/13825585.2021.192634.

Saffier B. Y., Lanting S. C., Koehle M. S., Klonsky E. D. and Iverson G. L. (2015). Assessing cognitive impairment using PROMIS® applied cognition-abilities scales in a medical outpatient sample. *Psychiatry Research*, 226, 169–172. DOI 10.1016/j.psychres.2014.12.043.

Schlosser M., Demnitz-King H., Whitfield T., Wirth M. and Marchant N. L. (2020). Repetitive negative thinking is associated with subjective cognitive decline in older adults: a cross-sectional study. *BMC Psychiatry*, 20, 500. DOI 10.1186/s12888-020-02884-7.

Sheehan, D. V., et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *Journal of Clinical Psychiatry*, 59, 22–33.

Smit D., Koerts J., Bangma D. F., Fuermaier A. B. M., Tucha L., Tucha O. (2021). Look who is complaining: psychological factors predicting subjective cognitive complaints in a large community sample of older adults. *Applied Neuropsychology: Adults*, 34, 1–15. DOI 10.1080/23279095.2021.2007387.

Steinley, D. (2006). K-means clustering: a half-century synthesis. *The British Journal of Mathematical and Statistical Psychology*, 59, 1–34. DOI 10.1348/000711095X48266.

Szymkowicz, S. M., Dotson, V. M. and Vanderploeg, R. D. (2020). Weak associations between depressive symptom severity, depressive symptom clusters, and cognitive performance in young to middle-aged men without clinical depression. *Aging, Neuropsychology, and Cognition*, 28, 921–935. DOI 10.1080/13825585.2020.1840505.

Takamiya, A., et al. (2021). Lower regional gray matter volume in the absence of higher cortical amyloid burden in late-life depression. *Scientific Reports*, 11, 15981. DOI 10.1038/s41598-021-95206-0.

Taylor, W. D., Aizenstein, H. J. and Alexopoulos, G. S. (2013). The vascular depression hypothesis: mechanisms linking vascular disease with depression. *Molecular Psychiatry*, 18, 963–974. DOI 10.1038/mp.2013.20.

Taylor, W. D., et al. (2020). Medial temporal lobe volumes in late-life depression: effects of age and vascular risk factors. *Brain Imaging and Behavior*, 14, 19–29. DOI 10.1007/s11682-018-9969-y.

Thomas, A. J., et al. (2009). A comparison of neurocognitive impairment in younger and older adults with major depression. *Psychological Medicine*, 39, 725–733. DOI 10.1017/S0033291708004042.

Ustun, T. B., & World Health Organization (2010). Measuring health and disability: Manual for WHO Disability Assessment Schedule WHODAS 2.0. Geneva: World Health Organization.

Verhaak P. F. M., Dekker J. H., de Waal M. W. M., van Marwijk H. W. J. and Comijs H. C. (2014). Depression, disability and somatic diseases among elderly. *Journal of Affective Disorders*, 167, 187–191. DOI 10.1016/j.jad.2014.05.057.

Ward, J. H. (1963). Hierarchical grouping to optimize an objective function. *Journal of the American Statistical Association*, 58, 236–244. DOI 10.2307/2282967.

Windgassen S., Moss-Morris R., Goldsmith K. and Chalder T. (2018). The importance of cluster analysis for enhancing clinical practice: an example from irritable bowel syndrome. *Journal of Mental Health*, 2, 94–96. DOI 10.1080/09638237.2018.1437615.

Wolf P. A., D’Agostino R. B., Belanger A. J. and Kannel W. B. (1991). Probability of stroke: a risk profile from the Framingham study. *Stroke*, 22, 312–318. DOI 10.1161/01.str.22.3.312.

Zlatar Z. Z., Muniz M., Galasko D. and Salmon D. P. (2018). Subjective cognitive decline correlates with depression symptoms and not with concurrent objective cognition in a clinic-based sample of older adults. *Journals of Gerontology - Series B Psychological Sciences and Social Sciences*, 73, 1198–1202. DOI 10.1093/geronb/gbw207.